Largazole: From discovery to broad-spectrum therapy
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chemical scaffold and potently inhibits class I histone deacetylases (HDACs). Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells. The intriguing structure and biological activity of largazole have attracted strong interest from the synthetic chemistry community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic. This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure-activity relationships, HDAC8-largazole thiol crystal structure, and biological studies, including in vivo anticancer and osteogenic activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in cellular contexts, the IC50 values of thiol HDACi decrease significantly, due to reduction/hydrolysis of prodrugs. Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [86]
In the citing paper
“Similarly, largazole (Figure 15A), a thioester, is recognized as a thioesterase substrate in cells and is hydrolyzed to release a free thiol as a ZBG (Figure 15B) [86, 87].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [86]
In the citing paper
“Cyanobacteria are known to be a rich source of highly bioactive natural products32–35, and in particular, protease inhibitors from numerous chemical classes36–41.”
From Native metabolomics identifies the rivulariapeptolide family of protease inhibitors (2022) · cites this paper as [32]
Citations
Cites
(2002) · PubMed · Cited by 732
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Marine Natural Products: A New Wave of Drugs?
Montaser, R., & Luesch, H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.118 · Cited by 437
Self-citationTaori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
Self-citationRole of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
Agathanggelou, A., Cooper, W. N., & Latif, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4088 · Cited by 388
Luesch, H., Moore, R. E., Paul, V. J., Mooberry, S. L., & Corbett, T. H. (2001) · Journal of Natural Products · doi:10.1021/np010049y · Cited by 378
Self-citationBiologically active secondary metabolites from marine cyanobacteria
Nunnery, J. K., Mevers, E., & Gerwick, W. H. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.09.019 · Cited by 265
PTEN Level in Tumor Suppression: How Much Is Too Little?
Carracedo, A., Alimonti, A., & Pandolfi, P. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2488 · Cited by 246
Kawai, H., Li, H., Avraham, S., Jiang, S., & Avraham, H. K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11403 · Cited by 226
Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
Ying, Y., Taori, K., Kim, H., Hong, J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8013727 · Cited by 222
Self-citation
Research works printed but not linked: 6
- Behar, 2010, Newsweek, 156, 40
- Furumai, 2002, Cancer Res., 62, 4916
- Ren, 2008, Synlett, 2379
- Numajiri, 2008, Synlett, 2483
- Wang, 2009, Synthesis, 2873
- Jeon, 2010, Int. J. Oncol., 37, 419
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Blunt, J. W., Copp, B. R., Keyzers, R. A., Munro, M. H. G., & Prinsep, M. R. (2014) · Natural Product Reports · doi:10.1039/c3np70117d · Cited by 484
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Bioactive thiazole and benzothiazole derivatives
Rouf, A., & Tanyeli, C. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.058 · Cited by 375
Branching Out: Rhodium-Catalyzed Allylation with Alkynes and Allenes
Koschker, P., & Breit, B. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00252 · Cited by 359
Microalgae in modern cancer therapy: current knowledge
Abd El-Hack, M. E., Abdelnour, S., Alagawany, M., Abdo, M., Sakr, M. A., Khafaga, A. F., Mahgoub, S. A., Elnesr, S. S., & Gebriel, M. G. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.069 · Cited by 206
Pharmaceutical applications of cyanobacteria—A review
Vijayakumar, S., & Menakha, M. (2015) · Journal of Acute Medicine · doi:10.1016/j.jacme.2015.02.004 · Cited by 205
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J.-P. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 178
“Selective toxicity in liver cancer exerted by tefinostat [236], encouraging results of clinical trials evaluating ricolinostat [230] in multiple myeloma, motivating results attained with aromatase inhibitor, exemestane and the orthoaminoanilide entinostat in the treatment of postmenopausal breast cancer [237], combina…”
Biological targets and mechanisms of action of natural products from marine cyanobacteria
Salvador-Reyes, L. A., & Luesch, H. (2015) · Natural Product Reports · doi:10.1039/c4np00104d · Cited by 162
Self-citationMazard, S., Penesyan, A., Ostrowski, M., Paulsen, I., & Egan, S. (2016) · Marine Drugs · doi:10.3390/md14050097 · Cited by 153
“were shown to have high activity towards HDAC: the potent and selective anti-proliferative santacruzamate A (Figure 2) [92] and the cyclic dipepsipeptide largazole specific to class I HDAC (Figure 2) [93–96].”
Muscarine, imidaozle, oxazole and thiazole alkaloids
Jin, Z. (2013) · Natural Product Reports · doi:10.1039/c3np70006b · Cited by 144
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Cappellacci, L., Perinelli, D. R., Maggi, F., Grifantini, M., & Petrelli, R. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867325666181016163110 · Cited by 130
Strategies to access biosynthetic novelty in bacterial genomes for drug discovery
Hemmerling, F., & Piel, J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00414-6 · Cited by 148
Heteroaryl Rings in Peptide Macrocycles
Smolyar, I. V., Yudin, A. K., & Nenajdenko, V. G. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00789 · Cited by 136
Advances in Exploring the Therapeutic Potential of Marine Natural Products
Liang, X., Luo, D., & Luesch, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104373 · Cited by 110
“For example, largazole[25,26] (Figure 3) was recognized as a prodrug and the active species, largazole thiol, is proposed to interact with Zn2+-dependent HDAC isoforms since the thiol motif is similar to that of other HDAC inhibitors, such as FK228.”
Self-citationWang, R., Paul, V. J., & Luesch, H. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.12.019 · Cited by 129
Self-citationItoh, H., & Inoue, M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00063 · Cited by 125
Goto, Y., Ito, Y., Kato, Y., Tsunoda, S., & Suga, H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.04.008 · Cited by 116
“As a consequence, these heterocycles contribute to the diverse bioactivities of this class of natural products (Degnan et al., 1989; Drechsel and Jung, 1998; Hong and Luesch, 2012; Melby et al., 2011; Scholz et al., 2011).”
E1 Enzymes as Therapeutic Targets in Cancer
Barghout, S. H., & Schimmer, A. D. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000053 · Cited by 118
Apratoxin H and Apratoxin A Sulfoxide from the Red Sea Cyanobacterium Moorea producens
Thornburg, C. C., Cowley, E. S., Sikorska, J., Shaala, L. A., Ishmael, J. E., Youssef, D. T. A., & McPhail, K. L. (2013) · Journal of Natural Products · doi:10.1021/np4004992 · Cited by 104
Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides
Kang, H., Choi, M.-C., Seo, C., & Park, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030919 · Cited by 97
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 98
Visible-Light-Driven Photocatalytic Initiation of Radical Thiol–Ene Reactions Using Bismuth Oxide
Fadeyi, O., Mousseau, J. J., Feng, Y., Allais, C., Nuhant, P., Chen, M. Z., Pierce, B. S., & Robinson, R. P. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b03184 · Cited by 101
Pavlik, C. M., Wong, C. Y. B., Ononye, S. N., Lopéz, D., Engene, N., McPhail, K. L., Gerwick, W. H., & Balunas, M. J. (2013) · Journal of Natural Products · doi:10.1021/np400198r · Cited by 103
Anticancer Agents from Diverse Natural Sources
Khazir, J., Riley, D. L., Pilcher, L. A., De-Maayer, P., & Mir, B. A. (2014) · Natural Product Communications · doi:10.1177/1934578x1400901130 · Cited by 95
“1 Marine derived compounds in clinical trials The first anticancer agent derived from marine organism to enter clinical trials was a cyclic depsipeptide didemnin B (63) isolated from Trididemnum solidum [281].”
Natural products as leads to antitumor drugs
Newman, D. J., & Giddings, L. (2013) · Phytochemistry Reviews · doi:10.1007/s11101-013-9292-6 · Cited by 78
“13), and analogues of the largazole thiol, together with extensive studies as to the mechanisms of action from an antitumor perspective (Benelkebir et al. 2011; Hong and Luesch 2012).”
Innovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
Fixierung cyclischer Peptide: Mimetika von Proteinstrukturmotiven
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie · doi:10.1002/ange.201401058 · Cited by 74
Natural Products Impacting DNA Methyltransferases and Histone Deacetylases
Akoné, S. H., Ntie‐Kang, F., Stuhldreier, F., Ewonkem, M. B., Noah, A. M., Mouelle, S. E. M., & Müller, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00992 · Cited by 72
“Compound 39 is a prodrug that requires activation through hydrolysis to form the thiol 40 as the active form exhibiting high isozyme-selective HDAC inhibition activity (Hong and Luesch, 2012).”
Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets
Tan, L. T., & Phyo, M. Y. (2020) · Molecules · doi:10.3390/molecules25092197 · Cited by 65
Ai, H., Lü, W., & Wu, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106079 · Cited by 64
Palladium-Catalyzed Thiocarbonylation of Alkenes toward Linear Thioesters
Ai, H., Zhao, F., Geng, H., & Wu, X. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c00414 · Cited by 63
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang, H., Chen, X., Li, K., Cheaito, H. A., Yang, Q., Wu, G., Liu, J., & Dou, Q. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.013 · Cited by 65
Ballante, F., & Marshall, G. R. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00603 · Cited by 66
Biosynthesis of depsipeptides, or Depsi: The peptides with varied generations
Alonzo, D. A., & Schmeing, T. M. (2020) · Protein Science · doi:10.1002/pro.3979 · Cited by 62
Dahiya, R., Dahiya, S., Fuloria, N. K., Kumar, S., Mourya, R., Chennupati, S. V., Jankie, S., Gautam, H., Singh, S. K., Karan, S. K., et al. (2020) · Marine Drugs · doi:10.3390/md18060329 · Cited by 75
“Largazole is a cyclic peptide with thiazole/thiazoline residues, including a number of unusual structural features, including a 3-hydroxy-7-mercaptohept-4-enoic acid unit and a 16-membered macrocyclic cyclodepsipeptide skeleton.”
InfluentialNatural Cyclopeptides as Anticancer Agents in the Last 20 Years
Zhang, J., Xia, Y.-X., & Zhang, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083973 · Cited by 58
“Taken together, largazole is suggested to activate osteogenesis [285].”
Darsih, C., Prachyawarakorn, V., Wiyakrutta, S., Mahidol, C., Ruchirawat, S., & Kittakoop, P. (2015) · RSC Advances · doi:10.1039/c5ra13735g · Cited by 65
Pharmaceutical agents from filamentous marine cyanobacteria
Tan, L. T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.010 · Cited by 67
Mazur‐Marzec, H., Fidor, A., Cegłowska, M., Wieczerzak, E., Kropidłowska, M., Goua, M., Macaskill, J. S., & Edwards, C. (2018) · Marine Drugs · doi:10.3390/md16070220 · Cited by 53
Morita, M., Ohno, O., Teruya, T., Yamori, T., Inuzuka, T., & Suenaga, K. (2012) · Tetrahedron · doi:10.1016/j.tet.2012.05.038 · Cited by 52
Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes
Maolanon, A. R., Kristensen, H. M. E., Leman, L. J., Ghadiri, M. R., & Olsen, C. A. (2017) · ChemBioChem · doi:10.1002/cbic.201600519 · Cited by 46
Native metabolomics identifies the rivulariapeptolide family of protease inhibitors
Reher, R., Aron, A. T., Fajtová, P., Stincone, P., Wagner, B., Pérez-Lorente, A. I., Liu, C., Shalom, I. Y. B., Bittremieux, W., Wang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32016-6 · Cited by 53
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)
Banerjee, P., Mandhare, A., & Bagalkote, V. S. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2012150 · Cited by 45
Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications
Ma, C., Cheng, J., Gu, J. H., & Wang, Q. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00373-5 · Cited by 66
“Largazole, a marine-derived thioester-containing depsipeptide, selectively targets class I HDACs and exhibits strong anti-proliferative activity in colon and pancreatic cancer models [80–83].”
Minhas, L. A., Kaleem, M., Farooqi, H. M. U., Kausar, F., Waqar, R., Bhatti, T., Aziz, S., Jung, D. W., & Mumtaz, A. S. (2024) · Algal Research · doi:10.1016/j.algal.2024.103396 · Cited by 51
Albert, B. J., Niu, A., Ramani, R., Marshall, G. R., Wender, P. A., Williams, R. M., Ratner, L., Barnes, A. B., & Kyei, G. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07814-4 · Cited by 48
Salvador, L. A., Park, H., Al‐Awadhi, F. H., Liu, Y., Kim, B., Zeller, S. L., Chen, Q.-Y., Hong, J., & Luesch, H. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500170r · Cited by 40
Self-citationEpigenetic modulators from “The Big Blue”: A treasure to fight against cancer
Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.005 · Cited by 42
Peptides as epigenetic modulators: therapeutic implications
Janssens, Y., Wynendaele, E., Berghe, W. V., & Spiegeleer, B. M. J. D. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0700-7 · Cited by 44
Progress in the discovery and development of anticancer agents from marine cyanobacteria
Luesch, H., Ellis, E. K., Chen, Q.-Y., & Ratnayake, R. (2024) · Natural Product Reports · doi:10.1039/d4np00019f · Cited by 43
Self-citationChen, Q.-Y., Chaturvedi, P. R., & Luesch, H. (2018) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00352 · Cited by 38
Self-citationEvaluation of class I HDAC isoform selectivity of largazole analogues
Kim, B., Park, H., Salvador, L. A., Serrano, P. E., Kwan, J. C., Zeller, S. L., Chen, Q.-Y., Ryu, S., Liu, Y., Byeon, S., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.07.006 · Cited by 38
Self-citationTotal Synthesis of (18S)‐ and (18R)‐Homolargazole by Rhodium‐Catalyzed Hydrocarboxylation
Schotes, C., Ostrovskyi, D., Senger, J., Schmidtkunz, K., Jung, M., & Breit, B. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201303300 · Cited by 37
Al‐Awadhi, F. H., Salvador‐Reyes, L. A., Elsadek, L. A., Ratnayake, R., Chen, Q.-Y., & Luesch, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00093 · Cited by 39
Self-citationCosta, M., Sampaio‐Dias, I. E., Castelo‐Branco, R., Scharfenstein, H. J., de Castro, R. R., Silva, A., Schneider, M. P. C., Araújo, M. J., Martins, R. F., Domingues, V. F., et al. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b01038 · Cited by 35
Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization
Barry, Z., Park, B., & Corson, T. W. (2020) · Molecules · doi:10.3390/molecules25153468 · Cited by 36
“Largazole is a natural macrocyclic depsipeptide isolated from the marine cyanobacterium Symploca species that selectively inhibits class I HDACs [179].”
Huo, Y., Qi, X., & Wu, X. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c01430 · Cited by 33
Clausen, D. J., Smith, W. B., Haines, B. E., Wiest, O., Bradner, J. E., & Williams, R. M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.063 · Cited by 33
“Of these thiols, the depsipeptide pyridine thiols 6, 8 show similar potency to Largazole thiol (2) and Largazole peptide isostere thiol (4) with IC50 values in the single digit nM range for HDACs 1–3.”
Synthesis of Thiazolines by Copper Catalyzed Aminobromination of Thiohydroximic Acids
Lemercier, B. C., & Pierce, J. G. (2014) · Organic Letters · doi:10.1021/ol500588v · Cited by 32
Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy
Conte, M., Fontana, E., Nebbioso, A., & Altucci, L. (2020) · Marine Drugs · doi:10.3390/md19010015 · Cited by 39
“Increased H3 acetylation (in vitro) [94] Macrocyclic depsipeptide Cyanobacterium Symplocasp HDAC inhibition (in vitro) [85,91]”
InfluentialBousquet, M. S., Ma, J., Ratnayake, R., Havre, P. A., Yao, J. G., Dang, N. H., Paul, V. J., Carney, T. J., Dang, L. H., & Luesch, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00860 · Cited by 34
Self-citationAlgae: A Robust Living Material Against Cancer
Xin, Z., Zhang, M., Cui, H., Ding, X., Zhang, T., Wu, L., Cui, H., Xue, Q., Chen, C., & Gao, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s423412 · Cited by 35
“, and it showed strong anticancer effects, leading to the downregulation of type 1 histone deacetylase (HDAC).(70) Phycocyanin is extracted from the microalga Spirulina and causes pathological changes and DNA fragmentation, upregulates Fas and ICAM expression, downregulates Bcl2 expression, and activates cystatin prot…”
Natural Products as Zinc‐Dependent Histone Deacetylase Inhibitors
Tan, S., & Liu, Z. (2015) · ChemMedChem · doi:10.1002/cmdc.201402460 · Cited by 35
Peptide Based Macrocycles: Selective Histone Deacetylase Inhibitors with Antiproliferative Activity
Rajak, H., Singh, A. J., Dewangan, P. K., Patel, V. S., Jain, S., Tiwari, S. K., Veerasamy, R., & Sharma, P. C. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320140006 · Cited by 33
An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Kim, B., & Hong, J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666141208105614 · Cited by 30
Self-citationMarine Depsipeptides as Promising Pharmacotherapeutic Agents
Rangel, M., de Santana, C. J. C., Pinheiro, A., Anjos, L., Barth, T., Júnior, O. R. P., Fontes, W., & Castro, M. S. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160526122130 · Cited by 33
Almaliti, J., Al-Hamashi, A. A., Negmeldin, A. T., Hanigan, C. L., Perera, L., Pflum, M. K. H., Casero, R. A., & Tillekeratne, L. M. V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01271 · Cited by 33
“Methyl 6′-(aminomethyl)-2,2′-bipyridine-6-carboxylate (23)—To a mixture of nitrile 50 (720 mg, 3 mmol) in MeOH (15 mL) and trifluoroacetic acid (1 mL) was added 5% Pd/C (70 mg, 5 wt%).”
Synthesis and biological evaluation of largazole zinc-binding group analogs
Kim, B., Ratnayake, R., Lee, H., Shi, G., Zeller, S. L., Li, C., Luesch, H., & Hong, J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.071 · Cited by 30
“[PubMed: 26054247] (n) Almaliti J, Al-Hamashi AA, Negmeldin AT, Hanigan CL, Perera L, Pflum MKH, Casero RA Jr, Tillekeratne LMV. Largazole analogues embodying radical changes in the depsipeptide ring: development of a more selective and highly potent analogue.”
InfluentialSelf-citationHashemi, P., & Sadowski, I. (2019) · Medicinal Research Reviews · doi:10.1002/med.21638 · Cited by 32
Discovery and Mechanism of Natural Products as Modulators of Histone Acetylation
Salvador, L. A., & Luesch, H. (2012) · Current Drug Targets · doi:10.2174/138945012802008973 · Cited by 32
Self-citationRegulated Cell Death Signaling Pathways and Marine Natural Products That Target Them
Guzmán, E. A. (2019) · Marine Drugs · doi:10.3390/md17020076 · Cited by 30
“Many marine natural compounds are known to affect histone deacetylases (HDAC) [37–39], with examples of them inducing apoptosis being largazole [40] and psammaplin A [41].”
Microbial cancer therapeutics: A promising approach
Diwan, D., Cheng, L., Usmani, Z., Sharma, M., Holden, N. J., Willoughby, N. A., Sangwan, N. S., Baadhe, R. R., Liu, C., & Gupta, V. K. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.003 · Cited by 28
Bai, Z., Chen, Q., Gu, J. J., Cai, C., Zheng, J., Sheng, W., Yi, S., Liu, F., & Wang, H. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c05030 · Cited by 28
Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update
Sala, G. D., Agriesti, F., Mazzoccoli, C., Tataranni, T., Costantino, V., & Piccoli, C. (2018) · Marine Drugs · doi:10.3390/md16120467 · Cited by 28
“Beyond acting as an inhibitor of class I histone deacetylases [86], 89 was reported to inhibit the ubiquitin-activating enzyme E1 (IC50 = 29 μM) [87].”
Synthesis of Quaternary-Substituted Thiazolines via Halocyclization of S-Allyl Thioimidate Salts
Parker, P. D., Lemercier, B. C., & Pierce, J. G. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b02299 · Cited by 26
Natural Products and Chemical Biology Tools: Alternatives to Target Epigenetic Mechanisms in Cancers
Lascano, S., Lopez, M., & Arimondo, P. B. (2018) · The Chemical Record · doi:10.1002/tcr.201800133 · Cited by 27
“Largazole [44] Isolated in 2008 from a cyanobacterium Symploca sp.”
Gacheva, G. V., & Gigova, L. G. (2014) · Open Life Sciences · doi:10.2478/s11535-014-0350-x · Cited by 35
One-Pot Synthesis of 2,4-Disubstituted Thiazoline from β-Azido Disulfide and Carboxylic Acid
Liu, Y., Liu, J., Qi, X., & Du, Y. (2012) · The Journal of Organic Chemistry · doi:10.1021/jo301030k · Cited by 25
Mass spectrometry-based assay for the rapid detection of thiol-containing natural products
Capehart, S. L., & Carlson, E. E. (2016) · Chemical Communications · doi:10.1039/c6cc07111b · Cited by 26
Zhou, H., Jiang, S., Chen, J., Ren, X., Jin, J., & Su, S. B. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.019 · Cited by 25
“The largazole structure–activity relationship (SAR) has been comprehensively reviewed (Hong and Luesch, 2012).”
Luo, Y., Wang, X., Liu, Q., He, Y., Li, J., Luo, S., & Zhu, Q. (2023) · Green Chemistry · doi:10.1039/d2gc04689j · Cited by 23
Recent progression of cyanobacteria and their pharmaceutical utility: an update
Bishoyi, A. K., Sahoo, C. R., & Padhy, R. N. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2062051 · Cited by 30
“Largazole (cyclic depsipeptide) Anticancer and osteogenic NR Hong & Luesch, 2012 Oscillatoria acutissima 25.”
Bhansali, P. R., Hanigan, C. L., Perera, L., Casero, R. A., & Tillekeratne, L. M. V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.009 · Cited by 22
Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status
Vasileva, A. V., Gladkova, M. G., Ashniev, G. A., Osintseva, E. D., Орлов, А. В., Kravchuk, E. V., Boldyreva, A., Burenin, A. G., Nikitin, P. I., & Orlova, N. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063103 · Cited by 24
Wang, M., Sun, X., Zhou, Y., Zhang, K., Lu, Y., Liu, J., Huang, Y., Wang, G., Jiang, S., & Zhou, G. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4993 · Cited by 19
“In a human colon cancer HCT116 xenograft mouse model, largazole significantly inhibited tumor growth with no obvious toxicity (29,48), indicating that largazole has high bioavailability and low toxicity.”
Wu, R.-Z., Zhou, H., Song, J., Xia, Q.-H., Hu, W., Mou, X., & Li, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01569 · Cited by 20
Anticancer Drugs and Potential Anticancer Leads Inspired by Natural Products
Kittakoop, P. (2015) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63460-3.00005-5 · Cited by 29
Biological function and small molecule inhibitors of histone deacetylase 11
Jia, G., Liu, J., Hou, X., Jiang, Y., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116634 · Cited by 20
Leão, P. N., Ramos, V., Gonçalves, P., Viana, F., Lage, O. M., Gerwick, W. H., & Vasconcelos, V. M. (2013) · Marine Drugs · doi:10.3390/md11041316 · Cited by 30
“While this approach has yielded and continues to yield promising results (e.g., largazole, see Hong and Luesch [10] and the that cyanobacterial metabolites may play, and thus, many bioactive metabolites may never be investigated for this reason [12].”
Bhatia, S., Makkar, R., Behl, T., Sehgal, A., Singh, S., Rachamalla, M., Mani, V., Iqbal, M. S., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27051539 · Cited by 19
Shang, R., Li, K., Shen, N., & Liu, C. (2022) · Synlett · doi:10.1055/a-1807-8282 · Cited by 18
Lee, H., Nihan, K., & Kwon, Y. R. (2025) · Marine Drugs · doi:10.3390/md23060233 · Cited by 21
“Consistent with these effects, largazole induces cell cycle arrest and apoptosis in various cancer models [28,50].”
Cai, C., Wang, F., Xiao, X., Sheng, W., Liu, S., Chen, J., Zheng, J., Xie, R., Bai, Z., & Wang, H. (2022) · Chemical Communications · doi:10.1039/d1cc06764h · Cited by 17
Largazole Pharmacokinetics in Rats by LC-MS/MS
Yu, M., Salvador, L. A., Sy, S. K. B., Tang, Y., Singh, R. S. P., Chen, Q.-Y., Liu, Y., Hong, J., Derendorf, H., & Luesch, H. (2014) · Marine Drugs · doi:10.3390/md12031623 · Cited by 17
“Largazole shows slightly higher potency than these two HDAC inhibitors [3,4].”
Self-citationLargazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21
Qiu, B., Tan, A., Tan, Y. Z., Chen, Q.-Y., Luesch, H., & Wang, X. (2021) · Marine Drugs · doi:10.3390/md19080471 · Cited by 17
Self-citationTamura, T., Inoue, M., Yoshimitsu, Y., Hashimoto, I., Ohashi, N., Tsumura, K., Suzuki, K., Watanabe, T., & Hohsaka, T. (2022) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20210409 · Cited by 16
Jeon, H., Kim, J. H., & Kim, S. (2023) · Natural Product Reports · doi:10.1039/d3np00032j · Cited by 17
Hill, R. A. (2013) · Annual Reports Section B (Organic Chemistry) · doi:10.1039/c3oc90008h · Cited by 17
Medicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
“Similarly, largazole (Figure 15A), a thioester, is recognized as a thioesterase substrate in cells and is hydrolyzed to release a free thiol as a ZBG (Figure 15B) [86, 87].”
Metadata
- Authors
- Hong, J., & Luesch, H.
- Affiliations
- Duke University (US)
- University of Florida (US)
- Corresponding author
- Hong, Jiyong
- Luesch, Hendrik
- Venue
- Natural Product Reports
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 29
- Issue
- 4
- Pages
- 449
- ISSN
- 0265-0568 (ISSN-L)
- 1460-4752
- PMC
- PMC4777309
- OpenAlex
- W2089288742
- Cited by
- 174
- References
- 47
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 14 · 2022: 16 · 2021: 13 · 2020: 16 · 2019: 13 · 2018: 14 · 2017: 6 · 2016: 8 · 2015: 11 · 2014: 20 · 2013: 12 · 2012: 6
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Natural Product Reports (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA138544)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- largazole, Symploca, cyclic depsipeptides, marine natural products, HDAC8, anticancer activity, osteogenic differentiation, structure-activity relationship, total synthesis, crystal structure, cancer therapy
- MeSH terms
- Cyanobacteria, Antineoplastic Agents, Biological Products, Humans, Marine Biology, Structure-Activity Relationship, Thiazoles, Molecular Structure, Depsipeptides, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.